Coral Laboratories Ltd. (BSE: 524506) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹189 Cr, it ranks #2,697 by market cap among the 6,197 Indian listed companies on FinBizNet, and #57 of 86 in Medicinal Chemicals and Botanical Products. At ₹524.00 (as of 16 Nov 2026), the share price is 22.8% below its 52-week high of ₹679.00 and 45.6% above its 52-week low of ₹360.00. The share price is up 7.8% over one year and down 5.7% over three months.
| Current Price | ₹524.00 |
|---|---|
| Market Cap | ₹189 Cr |
| BSE Code | 524506 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 11.4 |
| Return on Equity | 7.98% |
| Return on Assets | 3.58% |
| 52-Week Range | ₹360.00 – ₹679.00 |
| 1-Year Price Change | +7.8% |
| 3-Month Price Change | -5.7% |
| Beta (1Y) | 0.41 |
| Dividend Yield | 0.38% |
| Headquarters | Mumbai, Maharashtra |
| Website | corallab.com |
| Revenue | ₹30 Cr |
|---|---|
| Net Profit | ₹5 Cr |
| Net Margin | 18.2% |
| EPS (Basic) | ₹15.08 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Coral Laboratories Ltd. reported revenue of ₹30 Cr in Q1 FY27, up 57.4% from ₹19 Cr in Q1 FY26 and up 11.9% from ₹26 Cr in Q4 FY26. It posted a net profit of ₹5 Cr for the quarter, against a net profit of ₹3 Cr in Q1 FY26 (up 110.5%). Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹19 Cr (Q1 FY26) to ₹32 Cr (Q2 FY25). The company was profitable in each of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹30 Cr | ₹5 Cr | 18.2% |
| Q4 FY26 | ₹26 Cr | ₹5 Cr | 19.7% |
| Q3 FY26 | ₹22 Cr | ₹3 Cr | 12.9% |
| Q2 FY26 | ₹19 Cr | ₹6 Cr | 30.6% |
| Q1 FY26 | ₹19 Cr | ₹3 Cr | 13.6% |
| Q4 FY25 | ₹28 Cr | ₹3 Cr | 10.1% |
| Q3 FY25 | ₹23 Cr | ₹6 Cr | 26.7% |
| Q2 FY25 | ₹32 Cr | ₹6 Cr | 19.8% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 74.96% of Coral Laboratories Ltd.'s shares as of Mar 2026, against 75.00% in Mar 2025 (−0.04 percentage points). Delivery averaged 79.2% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic, anti-protozoal/anti-amebic, antimalarial drugs, antipsychotic drugs, and thyroid products; topical, oral antiseptic, and calcium preparations; mouthwashes; nutritional, protein, and iron supplements; kits; appetizers; and other products. It also provides sterile products, such as small volume liquid, cephalosporin, betalactam, and lyophilized injectables; eye, ear, and nose drops; nasal sprays and metered dose inhalers; and large volume parenteral. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/
1. Formulations-This segment manufactures and sells pharmaceutical formulations.
1. Pharmaceutical Formulations-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Coral Laboratories Ltd. | ₹189 Cr | 11.4 | 7.98% | ₹30 Cr | +7.8% |
Listed by market capitalisation. Ratios are shown for context only.
Coral Laboratories Ltd. is trading at ₹524.00, with a market capitalisation of ₹189 Cr.
Coral Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Coral Laboratories Ltd. has a P/E of 11.4 and a return on equity of 7.98%.
Coral Laboratories Ltd. is listed on the BSE under the scrip code 524506.
Coral Laboratories Ltd.'s share price is up 7.8% over one year and down 5.7% over three months. Its 52-week range is ₹360.00 to ₹679.00.
In Q1 FY27, Coral Laboratories Ltd. reported revenue of ₹30 Cr and net profit of ₹5 Cr, with basic EPS of ₹15.08 (standalone, parsed from the company's exchange filing).
Coral Laboratories Ltd. reported revenue of ₹30 Cr in Q1 FY27, up 57.4% from ₹19 Cr in Q1 FY26 and up 11.9% from ₹26 Cr in Q4 FY26.
Promoters held 74.96% of Coral Laboratories Ltd.'s shares as of Mar 2026, against 75.00% in Mar 2025 (−0.04 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.